BCAL Diagnostics Faces Adoption Challenge Despite Software and Telehealth Launch
BCAL Diagnostics has embedded referral forms for its early cancer detection tests into clinical software used by 97% of Australian GPs, launched a telehealth platform, and opened a Sydney clinic, gearing up for a multi-cancer test launch in June 2026.
- Referral forms live on Best Practice and Medical Director platforms
- Telehealth service EarlyDetection.com.au launched with Medmate
- Multi-cancer early detection test due June 2026
- Sydney CBD clinic opening for high-risk patients
- EarlyDetection platform registered in multiple international markets
National GP Software Integration Unlocks Broad Access
BCAL Diagnostics (ASX:BDX) has taken a significant step to scale distribution of its early cancer detection tests by embedding clinical referral forms directly into Best Practice and Medical Director, the dominant GP software platforms covering approximately 97% of Australian general practitioners. This integration establishes a streamlined national referral pathway that aligns with existing primary care workflows, where risk assessments and test referrals typically occur.
The move complements BCAL’s existing partnerships with Sonic Healthcare and Healius Pathology networks, which have already facilitated national access to their Avantect pancreatic and ovarian cancer tests. This infrastructure enhancement is poised to support wider adoption of BCAL’s test portfolio, including the upcoming multi-cancer early detection test slated for June 2026, addressing a pancreatic cancer market estimated to exceed A$250 million annually. It builds on BCAL’s recent expansion of its Avantect tests through major pathology providers across key states Avantect cancer blood tests.
Telehealth Launch and Sydney Clinic to Broaden Patient Reach
On 12 May 2026, BCAL launched EarlyDetection.com.au, a telehealth platform developed in partnership with Medmate, providing a medically supported alternative channel for patients to access early detection tests. Dr Martin A. Devitt has been appointed Medical Director of the newly established Centre for Early Detection, which will also operate a high-risk patient clinic in Sydney’s CBD. This clinic aims to offer comprehensive risk assessments and facilitate blood-based testing through direct medical consultation.
This telehealth and clinic expansion aligns with BCAL’s strategy to improve patient access beyond traditional referral pathways, potentially accelerating test uptake and early diagnosis. The EarlyDetection platform has also been registered in New Zealand, the UK, the USA, India, and other international markets, signalling BCAL’s ambition to scale its early detection technology globally.
Strategic Leadership and Product Pipeline Progress
BCAL’s Executive Chair Jayne Shaw emphasised the importance of integrating with existing healthcare workflows to facilitate broader national adoption of blood-based early cancer detection. This announcement follows the recent appointment of Anne-Louise Arnett as CEO, effective June 2026, tasked with accelerating commercial rollout and international expansion of BCAL’s test portfolio Anne-Louise Arnett as CEO.
The company’s portfolio includes BREASTESTplus™, a blood test designed to complement mammography for women with dense breasts, and the Avantect range targeting pancreatic and ovarian cancers. The imminent launch of the Avantect multi-cancer early detection test represents a key commercial milestone, potentially unlocking substantial market opportunities in Australia and beyond.
Bottom Line?
BCAL’s integration into GP software and telehealth launch set the stage for scaling early cancer detection, but market uptake and clinical adoption remain key hurdles to watch.
Questions in the middle?
- How quickly will GPs incorporate BCAL’s referral forms into routine practice?
- What patient volumes will the EarlyDetection telehealth platform generate post-launch?
- How will the multi-cancer test perform commercially against established screening methods?
